SFI
ANIK icon

Susquehanna Fundamental Investments’s Anika Therapeutics ANIK Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29,325
Closed -$762K – 372
2023
Q2 		$762K Sell
29,325
-8,560
-23% -$229K 0.03% 378
2023
Q1 		$1.09M Hold
37,885
– – 0.03% 498
2022
Q4 		$1.12M Hold
37,885
– – 0.02% 624
2022
Q3 		$902K Buy
+37,885
New +$872K 0.02% 836

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna Fundamental Investments's ANIK Position: Q3 2023 in Review

Susquehanna Fundamental Investments sold out of Anika Therapeutics (ANIK) in Q3 2023, closing a stake of 29,325 shares — an estimated $762K sold.

Susquehanna Fundamental Investments first reported a position in ANIK in Q3 2022 and held it in 4 quarters. The position peaked at $1.12M in Q4 2022. 116 funds tracked by Wall St. Rank hold ANIK as of Q3 2023.

  • Susquehanna Fundamental Investments reported no remaining Anika Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 29,325 Anika Therapeutics shares in Q3 2023, an estimated $762K.
  • Susquehanna Fundamental Investments first reported a position in Anika Therapeutics in Q3 2022 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Anika Therapeutics position peaked at $1.12M in Q4 2022.
  • 116 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2023, filed 14 Nov 2023.